Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk

Dow Jones

04/29

0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 29, 2026 02:59 ET (06:59 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2631569798"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631569798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631569798?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 14:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631569798","market":"sh","top_or_hot":-1,"title":"Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 02:59 ET (06:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-29 14:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 02:59 ET (06:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COH.AU","symbol_name":"COCHLEAR LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631569798","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631569798","pubTimestamp":1777445940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COH.AU":"COCHLEAR LTD","BK7007":"医疗保健设备"},"translate_title":"耳蜗牛市认为成交量压力是周期性的——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":0.9},"content_text":"0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 02:59 ET (06:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}